Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features

Lixia Sheng; Tongyu Li; Yun Li; Miao Zhou; Jiaping Wang; Yanli Lai; Yanli Zhang; Ping Yi; Qitian Mu; Guifang Ouyang

Heliyon (Sep 2023)

Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features

Lixia Sheng,
Tongyu Li,
Yun Li,
Miao Zhou,
Jiaping Wang,
Yanli Lai,
Yanli Zhang,
Ping Yi,
Qitian Mu,
Guifang Ouyang

Affiliations

Lixia Sheng: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Tongyu Li: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Yun Li: Kindstar Global Precision Medicine Institute, Wuhan, China; Department of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd., Wuhan, 430000, China
Miao Zhou: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Jiaping Wang: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Yanli Lai: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Yanli Zhang: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China
Ping Yi: Kindstar Global Precision Medicine Institute, Wuhan, China; Department of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd., Wuhan, 430000, China; Corresponding author. Kindstar Global Precision Medicine Institute, Wuhan, China.
Qitian Mu: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China; Stem Cell Transplantation Laboratory, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China; Corresponding author. Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China.
Guifang Ouyang: Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China; Ningbo Clinical Research Center for Hematologic Malignancies, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Ningbo, 315000, Zhejiang, People's Republic of China; Corresponding author. Department of Hematology, Pital of Ningbo University, No.59 Liuting Street, Ningbo, Zhejiang, People's Republic of China.

Journal volume & issue: Vol. 9, no. 9
p. e19342

Abstract

Read online

Background: Co-stimulatory molecules have been shown to enhance antitumor immune responses, but their role in Diffuse Large B-cell Lymphoma (DLBCL) remains unexplored. Methods: This study aimed to explore the molecular typing of DLBCL with co-stimulatory molecule genes and to construct a prognostic profile to improve treatment decisions and clinical outcomes. Results: We conducted the first comprehensive analysis of co-stimulatory molecules in DLBCL patients and identified five co-stimulatory molecule genes with prognostic and diagnostic values. Consensus cluster analysis based on these five co-stimulatory molecule genes revealed that the two identified clusters had different distribution patterns and prognostic differences. Co-stimulatory molecular correlation signatures were then constructed based on these five co-stimulatory molecular genes and validated in an external dataset, showing good performance in predicting patient prognosis. The signature is an independent risk factor for DLBCL patients and significantly correlates with clinical factors in patients and can be used as a complement to clinical factors. Furthermore, the signature was associated with the tumor immune microenvironment. Patients identified as being at high risk according to our signature exhibit high levels of immune cell infiltration microenvironment. Conclusions: In conclusion, our signature can provide clinicians with prognostic predictions and help guide the treatment of patients with DLBCL.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords